Ecopia BioSciences Inc.
TSX : EIA

Ecopia BioSciences Inc.

April 05, 2006 13:50 ET

Treatment of First Cancer Patient Initiated With Ecopia's ECO-4601

MONTREAL, QUEBEC--(CCNMatthews - April 5, 2006) - Ecopia BioSciences Inc. (TSX:EIA) is pleased to announce the initiation of dosing of its first patient in a Phase I clinical trial of its anticancer product candidate ECO-4601 at the Clinical Research Unit of the Sir Mortimer B. Davis - Jewish General Hospital (JGH), a McGill University Teaching Hospital. The Phase I is designed to test the safety and tolerability of ECO-4601.

Up to 30 patients suffering from one of six types of cancers and who are refractory to current chemotherapies will be recruited for this trial. Such cancers are glioblastomas, breast, prostate, ovarian, lung and colon cancers. The clinical trial involves a 21-day cycle during which escalating dosages of the compound will be tested in different patients via continuous infusion using ambulatory pumps for 14 days, followed by a seven-day rest.

"We are very pleased with ECO-4601's rapid progression in the clinic", commented Dr. Pierre Falardeau, President and Chief Executive Officer of Ecopia. "We filed our Clinical Trial Application at the end of 2005, received our No Objection Letter on February 2, 2006 and we are now starting the treatment of our first patient. This is a testimony to the hard work of our principal investigator and of all our employees and collaborators involved in this trial. As the Phase I progresses throughout 2006, we look forward to informing our shareholders of its progress."

About Ecopia

Ecopia is finding novel anticancer therapies from soil-dwelling microorganisms that are one of the most prolific sources of drugs. Our current focus is to advance our flagship compound, ECO-4601, through the different stages of clinical trials. ECO-4601 is a novel small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary brain tumor growth and other types of cancers. Just like well-known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from microorganisms that live in common soil. However, unlike these drugs that were discovered many decades ago, ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the DECIPHER® technology. The common shares of Ecopia are listed on the TSX (symbol: EIA).

Additional information about the Company can be obtained from Ecopia's website at www.ecopiabio.com.

About the JGH

Since 1934, the Sir Mortimer B. Davis - Jewish General Hospital, a McGill University teaching hospital, has provided "Care for All," serving patients from diverse religious, linguistic and cultural backgrounds in Montreal, throughout Quebec and beyond. As one of the province's largest acute-care hospitals, the JGH has achieved a reputation for excellence in key medical specialties by continually expanding and upgrading its facilities for clinical treatment and teaching, as well as research at the Lady Davis Institute for Medical Research. For more, please visit www.jgh.ca.


Certain statements in this press release that do not relate exclusively to historical facts are forward-looking statements. When used in this press release, the expressions "up to", "will be", "progresses", "look forward to", "advance", "is designed" and similar expressions, as they relate to ECO-4601, Ecopia or Ecopia's management are intended to identify forward-looking statements. These statements represent the Company's current expectations regarding future events. These forward-looking statements, including the expected timing and progress through the Phase I clinical trial, and the potential of ECO-4601 as a cancer therapeutic in regards to specific cancers such as glioblastoma and breast, prostate, ovarian, lung and colon cancers, are based on data from preclinical animal studies and are therefore subject to a number of risks and uncertainties, many of which are outside Ecopia's control. Actual results may therefore vary materially from the expectations expressed by the Company and depend on a number of factors, including the efficacy of ECO-4601 in treating specific cancers in human patients, the successful recruitment of patients and the timely completion of clinical trials, the availability of funds and resources to pursue development of ECO-4601 and the impact of general economic conditions. Investors are cautioned against placing undue reliance on forward-looking statements or forward-looking information. These forward-looking statements or forward-looking information should not be relied upon as representing the Company's views as of any date subsequent to the date the statements were originally made or information originally provided. A more complete discussion of the risks and uncertainties facing the Company appears in Ecopia's 2005 Annual Report under Management's Discussion and Analysis of Financial Position and Results of Operations for fiscal 2005 and the 2005 Annual Information Form available at www.sedar.com. Except as required by law, Ecopia does not undertake and disclaims any obligation to update or revise its forward looking statements or forward looking information whether as a result of new information, future events, or otherwise.

Contact Information

  • Ecopia BioSciences Inc.
    Anne-Marie Guertin
    Vice-President, Finance
    (514) 336-2700 ext. 402
    (514) 336-8827 (FAX)
    info@ecopiabio.com